PMC5019433_01
Skin lesions reflecting initial outcome after lenalidomide/celecoxib.. Notes: (A) Before treatment. (B) After 1 week of treatment. (C) After 3 weeks of treatment. (D) After six courses of azacitidine.
ott-9-5507Fig1.jpg
PMC5019433_01_ott-9-5507Fig1.jpg
f1-ott-9-5507
A 79-year-old woman with only a history of toxic thyroid adenoma (undergoing treatment with carbimazol) consulted the dermatologist in January 2014 because of an 8-month history of small, violet, cutaneous abdominal lesions that had spread to the lower extremities, neck, armpits, and scalp (Figure 1A). During the first 15 days of treatment, the skin lesions progressively reduced in size (Figure 1B and C), and total bilirubin and creatinine also normalized, thus leading to improved patient performance status. After six cycles, a PET/CT and bone marrow aspiration showed a complete metabolic response and full immunophenotypic disappearance of the malignant clone (Figures 1D and 2).
PET/CT evolution of cutaneous, nodal, hepatic, and splenic involvement.. Notes: (A) At diagnosis (black arrows pointing to skin, nodal, hepatic, and splenic involvement). (B) After six courses of azacitidine showing metabolic complete response.. Abbreviation: PET/CT, positron emission tomography-computed tomography.
ott-9-5507Fig2.jpg
PMC5019433_01_ott-9-5507Fig2.jpg
f2-ott-9-5507
After six cycles, a PET/CT and bone marrow aspiration showed a complete metabolic response and full immunophenotypic disappearance of the malignant clone (Figures 1D and 2).